Brind.
  1. Collaboration agreements for oncology candidates were signed between several major pharmaceutical companies.
  2. A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.
  3. Recursion Pharmaceuticals announced strategic alliances with Bayer, Sanofi, Roche, Merck, and Genentech.
  4. A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.

Hoffmann-La Roche and Recursion utilized an AI platform to identify novel targets, including an advanced neuroscience target, for early discovery.

1 report, 1 independent Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Hoffmann-La Roche and Recursion utilized an AI platform to identify novel targets, including an advanced neuroscience target, for early discovery.

Who's involved

What this event is mainly about
Hoffmann-La RocheRecursion (United States)

Keep exploring

Part of

A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research. All 1 developments

Within Collaboration agreements for oncology candidates were signed between several major pharmaceutical companies.

The entities involved

Related events

Coverage

Newest first; wire copies grouped